$3.05
0.65% day before yesterday
NYSE, Aug 01, 10:00 pm CET
ISIN
US02157Q1094
Symbol
ANRO

Alto Neuroscience Stock price

$3.05
+0.83 37.39% 1M
-1.13 27.03% 6M
-1.18 27.90% YTD
-6.76 68.91% 1Y
-12.95 80.94% 3Y
-12.95 80.94% 5Y
-12.95 80.94% 10Y
-12.95 80.94% 20Y
NYSE, Closing price Fri, Aug 01 2025
-0.02 0.65%
ISIN
US02157Q1094
Symbol
ANRO
Industry

Key metrics

Basic
Market capitalization
$82.6m
Enterprise Value
$-57.0m
Net debt
positive
Cash
$160.8m
Shares outstanding
27.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.0
P/B
0.6
Financial Health
Equity Ratio
85.3%
Return on Equity
-40.6%
ROCE
-42.5%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-69.3m | $-86.8m
EBIT
$-69.9m | $-77.1m
Net Income
$-63.2m | $-68.2m
Free Cash Flow
$-54.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-34.0% | -27.4%
EBIT
-33.9% | -12.4%
Net Income
-27.1% | -10.9%
Free Cash Flow
-21.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.0
Short interest
9.6%
Employees
78
Rev per Employee
$0.0
Show more

Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Alto Neuroscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Alto Neuroscience forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Alto Neuroscience forecast:

Buy
86%
Hold
14%

Financial data from Alto Neuroscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
91% 91%
-
- Research and Development Expense 47 47
17% 17%
-
-69 -69
34% 34%
-
- Depreciation and Amortization 0.58 0.58
23% 23%
-
EBIT (Operating Income) EBIT -70 -70
34% 34%
-
Net Profit -63 -63
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alto Neuroscience Stock News

Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
3 days ago
NEW YORK , July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
4 days ago
NEW YORK , July 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 2...
More Alto Neuroscience News

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Head office United States
CEO Amit Etkin
Employees 78
Founded 2019
Website www.altoneuroscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today